Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a BetZacks Investment Research • Friday
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)Seeking Alpha • Thursday
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases24/7 Wall Street • Thursday
Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The StockSeeking Alpha • Thursday
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire • Wednesday
Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 2824/7 Wall Street • 10/25/26
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketZacks Investment Research • 10/23/26
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 10/22/26
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026PRNewsWire • 10/21/26
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowZacks Investment Research • 10/20/26
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 YearsThe Motley Fool • 10/20/26
Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2The Motley Fool • 10/20/26
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.The Motley Fool • 10/18/26
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?Zacks Investment Research • 10/14/26
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with ObesityPRNewsWire • 10/14/26
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?Zacks Investment Research • 10/12/26